



REACH: non-regulatory announcement

1 April 2021

**PROTEOME SCIENCES PLC**  
("Proteome Sciences", "the Group", or "the Company")

**Investor Presentation**

Proteome Sciences PLC is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company's results for the year ended 31 December 2020 via the Investor Meet Company platform on Thursday, 8 April 2021 at 10.00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and select to meet Proteome Sciences PLC via: <https://www.investormeetcompany.com/proteome-sciences-plc/register-investor>

Investors who already follow Proteome Sciences PLC on the Investor Meet Company platform will automatically be invited.

**For further information please contact:**

**Proteome Sciences plc**

Mariola Soehngen M.D., Chief Executive Officer

Tel: +44 (0)20 7043 2116

Dr Ian Pike, Chief Scientific Officer

**Allenby Capital Limited (AIM Nominated Adviser & Broker)**

John Depasquale / Jeremy Porter – Corporate Finance

Tel: +44 (0) 20 3328 5656

Tony Quirke – Sales and Corporate Broking

**About Proteome Sciences plc. ([www.proteomics.com](http://www.proteomics.com))**

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.